Your browser is no longer supported. Please, upgrade your browser.
CORT Corcept Therapeutics Incorporated daily Stock Chart
Corcept Therapeutics Incorporated
Index- P/E13.07 EPS (ttm)1.28 Insider Own0.70% Shs Outstand111.50M Perf Week-8.54%
Market Cap1.86B Forward P/E12.70 EPS next Y1.32 Insider Trans-6.25% Shs Float103.15M Perf Month3.79%
Income162.40M PEG- EPS next Q0.17 Inst Own79.50% Short Float15.79% Perf Quarter5.70%
Sales159.20M P/S11.70 EPS this Y135.70% Inst Trans20.49% Short Ratio6.85 Perf Half Y-4.63%
Book/sh1.67 P/B10.00 EPS next Y45.79% ROA104.70% Target Price23.20 Perf Year67.17%
Cash/sh0.80 P/C20.97 EPS next 5Y-1.00% ROE131.40% 52W Range8.90 - 25.96 Perf YTD-7.53%
Dividend- P/FCF30.78 EPS past 5Y39.00% ROI85.00% 52W High-35.67% Beta1.96
Dividend %- Quick Ratio4.00 Sales past 5Y117.00% Gross Margin97.80% 52W Low87.64% ATR0.94
Employees136 Current Ratio4.20 Sales Q/Q123.90% Oper. Margin33.30% RSI (14)41.64 Volatility5.64% 5.78%
OptionableYes Debt/Eq0.00 EPS Q/Q2039.00% Profit Margin81.10% Rel Volume0.51 Prev Close16.94
ShortableYes LT Debt/Eq0.00 EarningsFeb 22 AMC Payout0.00% Avg Volume2.38M Price16.70
Recom2.00 SMA200.75% SMA50-10.73% SMA2000.10% Volume1,209,414 Change-1.42%
Mar-09-18Initiated B. Riley FBR, Inc. Buy $30
Aug-31-17Initiated Stifel Buy $20
Feb-02-17Initiated Ladenburg Thalmann Buy $14
Apr-21-15Initiated FBR Capital Outperform $12
Jan-13-14Downgrade Stifel Buy → Hold
Aug-09-13Downgrade Ladenburg Thalmann Buy → Neutral $3.30
Aug-09-13Downgrade Janney Buy → Neutral
Feb-21-12Reiterated JMP Securities Mkt Outperform $9 → $11
Jan-06-10Upgrade Ladenburg Thalmann Neutral → Buy $4
Jul-17-08Initiated Rodman & Renshaw Mkt Outperform $8
Jun-21-07Upgrade Punk, Ziegel & Co Mkt Perform → Accumulate
Mar-23-18 01:20PM  Edited Transcript of CORT earnings conference call or presentation 22-Feb-18 10:00pm GMT Thomson Reuters StreetEvents
Mar-15-18 05:00PM  Corcept Therapeutics Files Lawsuit Against Teva Pharmaceuticals for Infringement of Korlym Patents GlobeNewswire
Mar-12-18 12:45PM  Why Corcept Therapeutics Incorporated Lost 34% in February Motley Fool +5.20%
Mar-09-18 06:18PM  How Did Corcept Therapeutics Incorporateds (NASDAQ:CORT) 67.61% ROE Fare Against The Industry? Simply Wall St.
Mar-08-18 07:24PM  Corcept Plans Korlym Label Expansion, Pipeline in Progress Zacks
Mar-02-18 07:40AM  Wired News Sangamo Gets CTA from UK Agency for Evaluating SB-FIX for Treatment of Hemophilia B ACCESSWIRE
07:35AM  New Research: Key Drivers of Growth for Corcept Therapeutics, HubSpot, Tableau Software, Balchem, Steelcase, and Chimerix Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Feb-23-18 08:55AM  Corcept's (CORT) Earnings and Sales Meet Estimates in Q4 Zacks
Feb-22-18 06:31PM  Corcept misses 4Q profit forecasts Associated Press
04:05PM  Corcept Therapeutics Announces 2017 Financial Results and Positive Interim Results of Relacorilant Phase 2 Trial GlobeNewswire
01:00PM  Corcept Therapeutics Incorporated. to Host Earnings Call ACCESSWIRE
Feb-15-18 04:05PM  Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2017 Financial Results, Provide Corporate Update, Host Conference Call GlobeNewswire
Feb-13-18 05:12PM  Why Corcept Therapeutics Stock Gained 27.4% in January Motley Fool
Feb-07-18 07:16PM  Cramer's lightning round: Buy Target on its revamped stra... CNBC Videos
06:48PM  Cramer's lightning round: Buy Target on its revamped strategy CNBC
Feb-05-18 04:30PM  These Biotech Stocks Each Dived More Than 20% Is The Sell-Off Overdone? Investor's Business Daily -26.43%
03:40PM  Why Corcept Therapeutics Incorporated Stock Is Getting Clobbered Today Motley Fool
08:49AM  Corcept's stock tumbles after Teva submits NDA for generic Korlym MarketWatch
Feb-01-18 04:02PM  Biotech Roundup: Who's Popping On Drug, Merger, Earnings News? Investor's Business Daily +5.54%
08:30AM  Corcept Therapeutics Announces Fourth Quarter and Full-Year 2017 Preliminary Selected Financial Results; Provides 2018 Revenue Guidance GlobeNewswire
Jan-31-18 08:20AM  Todays Research Reports on Trending Tickers: Bellicum Pharmaceuticals and Corcept Therapeutics ACCESSWIRE
Jan-18-18 12:24PM  Harry Boxers four breakout stocks to watch include Universal Display MarketWatch +6.26%
Jan-10-18 05:59PM  Corcept Therapeutics Stock Has Healthy Institutional Support Investopedia
Jan-05-18 08:10AM  Analysis: Positioning to Benefit within Perry Ellis International, AutoZone, Corcept Therapeutics, LCI Industries, LegacyTexas Financial Group, and Micronet Enertec Technologies Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jan-03-18 10:03AM  Trevena Announces FDA Acceptance of Olinvo NDA, Shares Up Zacks
09:55AM  Achaogen's NDA for Plazomicin Gets Priority Review From FDA Zacks
Dec-29-17 11:45AM  ETFs with exposure to Corcept Therapeutics, Inc. : December 29, 2017 Capital Cube
09:55AM  TherapeuticsMD Submits NDA for VMS Candidate, Shares Rise Zacks
Dec-28-17 07:05PM  What Should We Expect From Corcept Therapeutics Incorporateds (NASDAQ:CORT) Earnings Over The Next Few Years? Simply Wall St.
09:45AM  Actinium Posts Positive DMC View on Lomab-B Phase III Trial Zacks
09:21AM  Horizon Pharma Gets FDA Nod for Procysbi Label Expansion Zacks
Dec-27-17 11:29AM  Insys' Cannabidiol Gets Fast Track Designation in the U.S. Zacks -6.23%
08:14AM  Why is Corcept's Stock Up More Than 150% So Far This Year? Zacks
08:11AM  Alexion's (ALXN) Soliris Label Expansion Approved in Japan Zacks
Dec-26-17 09:45AM  Merck's Diabetes Drugs Get FDA Nod as Adjunct Therapies Zacks +5.03%
09:17AM  BioMarin's (BMRN) Pegvaliase Review Period Extended by FDA Zacks
Dec-25-17 07:17AM  Corcept Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CORT-US : December 25, 2017 Capital Cube
Dec-22-17 08:30AM  Strength Seen in Corcept Therapeutics (CORT): Stock Soars 10.8% Zacks
03:00AM  Corcept Therapeutics Shows Rising Price Performance With Jump To 95 RS Rating Investor's Business Daily
Dec-21-17 05:20PM  Why Corcept Therapeutics Shares Climbed 10.8% Today Motley Fool +10.82%
04:15PM  This Biotech Stock Launched After Joining The S&P 600 SmallCap Investor's Business Daily
10:35AM  Allergan/Paratek's Acne Candidate NDA Filing Accepted by FDA Zacks
Dec-20-17 05:44PM  Interactive Brokers Group Set to Join S&P MidCap 400; Holdings and Corcept Therapeutics to Join S&P SmallCap 600 PR Newswire
Dec-19-17 09:53AM  Regeneron in Strategic Immuno-Oncology Collaboration With ISA Zacks
09:28AM  Alnylam/Sanofi Submit MAA in Europe for RNAi Candidate Zacks
Dec-18-17 05:52PM  Novartis (NVS) Oncology Head Strigini to Step Down by Dec. 31 Zacks
05:45PM  Radius Health to Get Third Day-180 List of Outstanding Issues Zacks
09:37AM  Spectrum Pharma Dismisses CEO, Makes Leadership Changes Zacks
Dec-13-17 05:45PM  Regeneron, Sanofi Report Positive Top Line Skin Cancer Data Zacks
03:46PM  Allergan Inks Deal to Buy Texas-Based Repros Therapeutics Zacks
01:01PM  ETFs with exposure to Corcept Therapeutics, Inc. : December 13, 2017 Capital Cube
09:40AM  Glaxo's Nucala Label Expansion Application Gets FDA Approval Zacks
Dec-12-17 05:58PM  Merck's Keytruda Gets FDA Priority Review for Rare Lymphoma Zacks
10:15AM  Spark Therapeutics Stock Plunges on Hemophilia Therapy Data Zacks
Dec-11-17 02:12PM  Lilly Reports Mixed Results from Late-Stage Cyramza Study Zacks
Dec-07-17 04:28PM  5 Health Care Stocks Gurus Are Buying
02:21PM  Roche Reports Tecentriq/Avastin Lung Cancer Study Data Zacks
Dec-06-17 02:10PM  Revance's Neuromodulator Injection Positive in Phase III Zacks
Dec-05-17 09:46AM  Here's Why Sarepta Stock is Up More Than 70% in 6 Months Zacks
09:05AM  Ironwood Succeeds in Diabetic Hypertension Phase II Study Zacks
Dec-04-17 08:07AM  3 Highest Growth Stocks in the Market Today Motley Fool -8.35%
Dec-01-17 06:14PM  Bristol-Myers' Opdivo's Lung Cancer Study Meets Early Success Zacks
05:51PM  Celldex Begins Phase I Trial on Cancer Candidate CDX-1140 Zacks
Nov-29-17 09:52AM  AstraZeneca's Tagrisso Label Expansion Filing Accepted by EMA Zacks
Nov-22-17 08:42AM  Valeant Closes Senior Note Offering, Reprices Term Loan Zacks
Nov-21-17 12:37PM  Edited Transcript of CORT earnings conference call or presentation 2-Nov-17 9:00pm GMT Thomson Reuters StreetEvents
09:15AM  Can Valeant (VRX) Turn Around on Rebuilding Initiatives? Zacks
Nov-20-17 04:07PM  Mallinckrodt (MNK) Down 55% Year to Date: What Lies Ahead? Zacks -7.07%
10:02AM  Roche Reports Positive Data From Tecentriq Combination Study Zacks
08:10AM  Todays Research Reports on Trending Tickers: Catalyst Biosciences and Corcept Therapeutics ACCESSWIRE
07:57AM  Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : November 20, 2017 Capital Cube
Nov-17-17 09:01AM  Alnylam Starts Rolling NDA Submission for RNAi Candidate Zacks
Nov-16-17 07:55AM  Incyte (INCY) Initiates Essential Thrombocythemia Trial Zacks
Nov-15-17 12:07PM  Valeant (VRX) Announces Pricing of Senior Secured Notes Zacks
11:20AM  Roche (RHHBY) Receives FDA Clearance for Ventana MMR Test Zacks
10:19AM  Pacira's Exparel sNDA to be Reviewed by FDA Advisory Committee Zacks
06:36AM  Cardinal Health (CAH) to Divest Assets to Shanghai Pharma Zacks
Nov-14-17 10:09AM  Shire Gets Positive CHMP Opinion for Hemophilia A Drug Zacks
10:05AM  Alnylam RNAi Drug Gets Accelerated Assessment Grant From EMA Zacks
09:48AM  Glaxo's Subcutaneous Formulation of Benlysta Approved in EU Zacks
Nov-13-17 12:05PM  ETFs with exposure to Corcept Therapeutics, Inc. : November 13, 2017 Capital Cube
Nov-10-17 07:55AM  The Zacks Analyst Blog Highlights: Micron Technology, Meritor, RH, Ultra Clean Holdings and Corcept Therapeutics Zacks
Nov-09-17 04:25PM  5 Stocks That Doubled in 2017 and Can Keep Soaring Higher Zacks
07:10AM  Featured Company News Nektar Presented Preclinical Data on NKTR-358 at 2017 American College of Rheumatology Annual Meeting ACCESSWIRE
Nov-08-17 10:52AM  Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : November 8, 2017 Capital Cube
Nov-07-17 08:15AM  Corcept Therapeutics, Inc. :CORT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017 Capital Cube
Nov-06-17 08:00AM  Today's Research Reports on Stocks to Watch: Clean Energy Fuels Corp. and Corcept Therapeutics ACCESSWIRE +5.08%
07:48AM  Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : November 6, 2017 Capital Cube
Nov-03-17 03:32PM  Why Investors Should Be Excited About Corcept Therapeutics Plunging as Much as 18% Motley Fool -12.13%
03:14PM  Corcept (CORT) Q3 Earnings Miss Estimates, Guidance Raised Zacks
Nov-02-17 06:58PM  Corcept misses 3Q profit forecasts Associated Press
05:34PM  Small-Cap Biotech Dips As Sales Top, But Earnings Miss By 2 Cents Investor's Business Daily
04:05PM  Corcept Therapeutics Announces Third Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update GlobeNewswire
Nov-01-17 12:01PM  ETFs with exposure to Corcept Therapeutics, Inc. : November 1, 2017 Capital Cube
Oct-26-17 04:05PM  Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call GlobeNewswire
Oct-24-17 07:33AM  3 Small, Profitable Biotechs With Fantastic Growth Motley Fool
Oct-20-17 10:09AM  ETFs with exposure to Corcept Therapeutics, Inc. : October 20, 2017 Capital Cube
Oct-16-17 08:20AM  Today's Research Reports on Trending Tickers: Corcept Therapeutics and Orexigen Therapeutics ACCESSWIRE +5.30%
Oct-10-17 04:01PM  Weakness In Corcept Shares Is 'Overdone,' According To Analyst Benzinga -5.94%
01:39PM  Can Corcept Therapeutics Incorporateds (CORT) ROE Continue To Surpass The Industry Average? Simply Wall St.
Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression. It is developing relacorilant that is in a Phase II trial to treat patients with Cushing's syndrome; abraxane in combination with relacorilant, which is in Phase I/II open label trial to treat solid tumors; and selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer. The company is also developing CORT118335 selective cortisol modulator, which is in Phase I/II open label trial for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FISHMAN ROBERT SChief Medical OfficerMar 07Option Exercise3.518,00028,0808,000Mar 08 07:11 PM
GALA RENEE DDirectorMar 07Buy15.539,000139,80210,000Mar 07 08:38 PM
FISHMAN ROBERT SChief Medical OfficerMar 07Sale15.678,000125,3230Mar 08 07:11 PM
GALA RENEE DDirectorMar 06Buy15.301,00015,3001,000Mar 07 08:38 PM
FISHMAN ROBERT SChief Medical OfficerFeb 07Option Exercise3.518,00028,0808,000Feb 09 08:12 PM
FISHMAN ROBERT SChief Medical OfficerFeb 07Sale16.608,000132,7740Feb 09 08:12 PM
FISHMAN ROBERT SChief Medical OfficerJan 08Option Exercise3.518,00028,0808,000Jan 10 05:05 PM
FISHMAN ROBERT SChief Medical OfficerJan 08Sale18.678,000149,3490Jan 10 05:05 PM
FISHMAN ROBERT SChief Medical OfficerDec 08Option Exercise3.518,00028,0808,000Dec 12 05:15 PM
FISHMAN ROBERT SChief Medical OfficerDec 08Sale16.728,000133,7760Dec 12 05:15 PM
BAKER G LEONARD JRDirectorNov 13Option Exercise2.7030,00081,000806,838Nov 15 05:27 PM
BAKER G LEONARD JRDirectorNov 13Sale17.5930,000527,556776,838Nov 15 05:27 PM
MAHONEY DAVID LDirectorJul 19Option Exercise2.2316,91537,7201,152,588Jul 20 09:09 PM
MAHONEY DAVID LDirectorJul 19Sale12.5016,915211,4581,135,673Jul 20 09:09 PM
MAHONEY DAVID LDirectorJul 18Option Exercise2.236,09113,5831,141,764Jul 20 09:09 PM
MAHONEY DAVID LDirectorJul 18Sale12.506,09176,1391,135,673Jul 20 09:09 PM
MAHONEY DAVID LDirectorJul 13Sale12.554846,0731,128,679Jul 14 05:35 PM
MAHONEY DAVID LDirectorJul 12Sale12.506,51081,3751,129,163Jul 14 05:35 PM
Robb Gary CharlesChief Financial OfficerMay 04Buy9.755,60054,5886,858May 08 05:14 PM